These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

466 related articles for article (PubMed ID: 32175799)

  • 1. The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options.
    Periman LM; Perez VL; Saban DR; Lin MC; Neri P
    J Ocul Pharmacol Ther; 2020 Apr; 36(3):137-146. PubMed ID: 32175799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FTY720 ameliorates Dry Eye Disease in NOD mice: Involvement of leukocytes inhibition and goblet cells regeneration in ocular surface tissue.
    Xiao W; Xu GT; Zhang J; Zhang J; Zhang Y; Ye W
    Exp Eye Res; 2015 Sep; 138():145-52. PubMed ID: 26187517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LFA-1/ICAM-1 Interaction as a Therapeutic Target in Dry Eye Disease.
    Pflugfelder SC; Stern M; Zhang S; Shojaei A
    J Ocul Pharmacol Ther; 2017; 33(1):5-12. PubMed ID: 27906544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifitegrast for the treatment of dry eye disease in adults.
    Donnenfeld ED; Perry HD; Nattis AS; Rosenberg ED
    Expert Opin Pharmacother; 2017 Oct; 18(14):1517-1524. PubMed ID: 28841079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lifitegrast: First LFA-1/ICAM-1 antagonist for treatment of dry eye disease.
    Paton DM
    Drugs Today (Barc); 2016 Sep; 52(9):485-493. PubMed ID: 27883115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A new approach for better comprehension of diseases of the ocular surface].
    Baudouin C
    J Fr Ophtalmol; 2007 Mar; 30(3):239-46. PubMed ID: 17417148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Comprehensive Review of the Clinical Trials Conducted for Dry Eye Disease and the Impact of the Vehicle Comparators in These Trials.
    Nichols KK; Evans DG; Karpecki PM
    Curr Eye Res; 2021 May; 46(5):609-614. PubMed ID: 33238774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease.
    Perez VL; Pflugfelder SC; Zhang S; Shojaei A; Haque R
    Ocul Surf; 2016 Apr; 14(2):207-15. PubMed ID: 26807723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of Nano-ophthalmology in Treating Dry Eye Disease.
    Natesan S; Boddu SHS; Krishnaswami V; Shahwan M
    Pharm Nanotechnol; 2020; 8(4):258-289. PubMed ID: 32600244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Molecular Mechanisms Responsible for Tear Hyperosmolarity-Induced Pathological Changes in the Eyes of Dry Eye Disease Patients.
    Harrell CR; Feulner L; Djonov V; Pavlovic D; Volarevic V
    Cells; 2023 Dec; 12(23):. PubMed ID: 38067183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tear biomarkers in dry eye disease: Progress in the last decade.
    Kumar NR; Praveen M; Narasimhan R; Khamar P; D'Souza S; Sinha-Roy A; Sethu S; Shetty R; Ghosh A
    Indian J Ophthalmol; 2023 Apr; 71(4):1190-1202. PubMed ID: 37026250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists.
    Sheppard J; Shen Lee B; Periman LM
    Ann Med; 2023 Dec; 55(1):241-252. PubMed ID: 36576348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [TOPICAL ANTI-INFLAMMATORY AGENTS FOR DRY EYE DISEASE].
    Erdinest N; Solomon A
    Harefuah; 2019 Feb; 158(2):130-135. PubMed ID: 30779493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dry eye disease treatment: the role of tear substitutes, their future, and an updated classification.
    Barabino S; Benitez-Del-Castillo JM; Fuchsluger T; Labetoulle M; Malachkova N; Meloni M; Utheim TP; Rolando M
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8642-8652. PubMed ID: 32964952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifitegrast (Xiidra) for dry eye disease.
    Med Lett Drugs Ther; 2016 Aug; 58(1502):110-1. PubMed ID: 27552207
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-Inflammatories in the Treatment of Dry Eye Disease: A Review.
    Perez VL; Mah FS; Willcox M; Pflugfelder S
    J Ocul Pharmacol Ther; 2023 Mar; 39(2):89-101. PubMed ID: 36796014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Human Tear Proteome Following Topical Treatment of Dry Eye Disease: Cyclosporine A Versus Diquafosol Tetrasodium.
    Ji YW; Kim HM; Ryu SY; Oh JW; Yeo A; Choi CY; Kim MJ; Song JS; Kim HS; Seo KY; Kim KP; Lee HK
    Invest Ophthalmol Vis Sci; 2019 Dec; 60(15):5035-5044. PubMed ID: 31800960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease.
    Semba CP; Gadek TR
    Clin Ophthalmol; 2016; 10():1083-94. PubMed ID: 27354762
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.